Skip to main content
Fig. 7 | Journal of Experimental & Clinical Cancer Research

Fig. 7

From: Integrative analysis of bulk and single-cell gene expression profiles to identify tumor-associated macrophage-derived CCL18 as a therapeutic target of esophageal squamous cell carcinoma

Fig. 7

Tumor inhibition of the 4-NQO induced ESCC mouse model by a CCL18 peptide inhibitor. (A) Schematic illustration of the establishment and verification of the ESCC model. The ESCC mice were randomly divided into the NS or Pep3 treatment groups, and treated with 10 mg/kg of Pep3 for 8 days. (B) The body weight of the ESCC mice treated with NS or Pep3. (C) Survival curve of the ESCC mice (n = 8 for NS, n = 7 for Pep3). (D) Tumors of represented with the whole esophageal tissues, the numbers of the tumors and the total long diameter of the tumors were recorded (n = 3–4). *P < 0.05, **P < 0.01. (E) The representative flow cytometry plots and summary data of CD8+ or CD4+ T cells in the spleen of the ESCC mice (n = 3 or 5). ns, no significance, *P < 0.05. (F) The representative flow cytometry plots and summary data of macrophages or M1/M2 ratio in the spleen of the ESCC mice (n = 3 or 5). ns, no significance, *P < 0.05. (G) The H&E staining and immunostaining of the esophageal tissues of ESCC mice after treatment. The representative figures were obtained from serial section slides

Back to article page